Wyndham H Wilson, Ryan M Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, George Wright, Chih-Jian Lih, P Mickey Williams, Arthur L Shaffer, John Gerecitano, Sven de Vos, Andre Goy, Vaishalee P Kenkre, Paul M Barr, Kristie A Blum, Andrei Shustov, Ranjana Advani, Nathan H Fowler, Julie M Vose, Rebecca L Elstrom, Thomas M Habermann, Jacqueline C Barrientos, Jesse McGreivy, Maria Fardis, Betty Y Chang, Fong Clow, Brian Munneke, Davina Moussa, Darrin M Beaupre, Louis M Staudt. Nat Med 2015
Times Cited: 671
Times Cited: 671
Grzegorz S Nowakowski, Betsy LaPlant, William R Macon, Craig B Reeder, James M Foran, Garth D Nelson, Carrie A Thompson, Candido E Rivera, David J Inwards, Ivana N Micallef, Patrick B Johnston, Luis F Porrata, Stephen M Ansell, Randy D Gascoyne, Thomas M Habermann, Thomas E Witzig. J Clin Oncol 2015
Times Cited: 266
Times Cited: 266
List of shared articles
Times cited
DLBCL 1L-What to Expect beyond R-CHOP?
Maike Stegemann, Sophy Denker, Clemens A Schmitt. Cancers (Basel) 2022
Maike Stegemann, Sophy Denker, Clemens A Schmitt. Cancers (Basel) 2022
Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic Strategies.
Michael R Cook, Kieron Dunleavy. Curr Oncol Rep 2022
Michael R Cook, Kieron Dunleavy. Curr Oncol Rep 2022
Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge.
Daniele Lavacchi, Ida Landini, Gabriele Perrone, Giandomenico Roviello, Enrico Mini, Stefania Nobili. Pharmacol Ther 2022
Daniele Lavacchi, Ida Landini, Gabriele Perrone, Giandomenico Roviello, Enrico Mini, Stefania Nobili. Pharmacol Ther 2022
Inferring gene expression from cell-free DNA fragmentation profiles.
Mohammad Shahrokh Esfahani, Emily G Hamilton, Mahya Mehrmohamadi, Barzin Y Nabet, Stefan K Alig, Daniel A King, Chloé B Steen, Charles W Macaulay, Andre Schultz, Monica C Nesselbush,[...]. Nat Biotechnol 2022
Mohammad Shahrokh Esfahani, Emily G Hamilton, Mahya Mehrmohamadi, Barzin Y Nabet, Stefan K Alig, Daniel A King, Chloé B Steen, Charles W Macaulay, Andre Schultz, Monica C Nesselbush,[...]. Nat Biotechnol 2022
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.
Keenan T Hartert, Kerstin Wenzl, Jordan E Krull, Michelle Manske, Vivekananda Sarangi, Yan Asmann, Melissa C Larson, Matthew J Maurer, Susan Slager, William R Macon,[...]. Leukemia 2021
Keenan T Hartert, Kerstin Wenzl, Jordan E Krull, Michelle Manske, Vivekananda Sarangi, Yan Asmann, Melissa C Larson, Matthew J Maurer, Susan Slager, William R Macon,[...]. Leukemia 2021
Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
Mary-Kate Malecek, Marcus P Watkins, Nancy L Bartlett. Expert Opin Biol Ther 2021
Mary-Kate Malecek, Marcus P Watkins, Nancy L Bartlett. Expert Opin Biol Ther 2021
Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma.
Hua-Jay J Cherng, Jason Westin. Leuk Lymphoma 2021
Hua-Jay J Cherng, Jason Westin. Leuk Lymphoma 2021
Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Brian G Bazzell, Lydia L Benitez, Bernard L Marini, Anthony J Perissinotti, Tycel J Phillips, Victoria R Nachar. Clin Lymphoma Myeloma Leuk 2021
Brian G Bazzell, Lydia L Benitez, Bernard L Marini, Anthony J Perissinotti, Tycel J Phillips, Victoria R Nachar. Clin Lymphoma Myeloma Leuk 2021
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.
Sriram Balasubramanian, Songbai Wang, Christopher Major, Brendan Hodkinson, Michael Schaffer, Laurie H Sehn, Peter Johnson, Pier Luigi Zinzani, Jodi Carey, S Martin Shreeve,[...]. Br J Haematol 2021
Sriram Balasubramanian, Songbai Wang, Christopher Major, Brendan Hodkinson, Michael Schaffer, Laurie H Sehn, Peter Johnson, Pier Luigi Zinzani, Jodi Carey, S Martin Shreeve,[...]. Br J Haematol 2021